543904

Mankind Pharma Limited will participate in an Investor Conference organized by Bank of America on June 1, 2026, and meet with various investors on June 2, 2026, in Mumbai. The company confirmed that no unpublished price sensitive information would be disclosed during these interactions, with discussions based on the general business outlook and information already in the public domain.

Management guided for double-digit top-line growth in FY27, aiming to outperform IQVIA. The FY27 EBITDA margin is projected to be 25.5-26.5%, an improvement over FY26 adjusted margin. Capex for FY27 is estimated at 6-7% of revenue, including ₹500 crores for a new Vadodara biotech facility. The effective tax rate will increase to 25-26% in FY27 due to the end of the Sikkim exemption. The company is on track to repay acquisition debt by FY28, targeting a net debt to adjusted EBITDA ratio of 0.5x for FY27. Growth drivers include acute portfolio normalization, chronic therapy momentum, specialty products (including GLP-1 pen launch), and high double-digit growth in international markets.

Mankind Pharma Limited announced that its management and officials will participate in investor meetings with various investors in Singapore on May 25-26, 2026. The company clarified that no unpublished price sensitive information will be disclosed, and discussions will focus on the general business outlook and information already in the public domain.

Mankind Pharma Limited has informed that the audio recording of the Investor Conference Call for Q4 & FY26, held on May 20, 2026, is now available on the company's website. This filing is in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and is for investor reference.

Consolidated Revenue from Operations for Q4 FY26 increased to ₹3,443 Cr from ₹3,079 Cr (▲11.8% YoY). Adjusted EBITDA grew to ₹933 Cr from ₹711 Cr (▲31.1% YoY), and Net Profit (PAT) rose to ₹559 Cr from ₹429 Cr (▲30.4% YoY). Adjusted EBITDA Margin expanded to 27.1% from 23.1% (▲400bps) YoY.

Mankind Pharma Limited's Nomination and Remuneration Committee approved the allotment of 80,872 equity shares, face value ₹1/-, on May 19, 2026, to eligible employees under the ESOP Plan 2022. This allotment increases the paid-up share capital from 41,28,28,328 to 41,29,09,200 equity shares, which rank pari-passu with existing shares.

Standalone Revenue ₹2,581.82Cr vs ₹2,119.46Cr (▲21.80% YoY), EBITDA ₹896.02Cr vs ₹341.84Cr (▲162.15% YoY), PAT ₹713.61Cr vs ₹235.16Cr (▲203.46% YoY) for the quarter ended March 31, 2026. EBITDA Margin 34.70% vs 16.13% (▲1857bps). The Board also approved an additional investment of up to ₹500 Cr in Mankind Medicare Private Limited and noted the decision of Executive Directors to forgo commission for FY 2025-26 to strengthen cash position. Mr. Pramod Gokhale, Global Chief Information Officer, resigned.

Mankind Pharma reported strong consolidated results for Q4 FY26. Consolidated Revenue stood at ₹3,442.93 Cr vs ₹3,079.37 Cr (▲11.81% YoY), EBITDA at ₹909.71 Cr vs ₹685.51 Cr (▲32.70% YoY), and PAT at ₹559.42 Cr vs ₹428.99 Cr (▲30.40% YoY). EBITDA Margin expanded to 26.42% vs 22.26% (▲416bps). The Board also approved re-appointment of Mr. Satish Kumar Sharma as Whole-Time Director, re-appointment of Cost Auditors, and an additional investment of up to ₹500 crores in Mankind Medicare Private Limited. Executive Directors decided not to draw commission for FY26 to strengthen cash position for business expansion.

Standalone Revenue ₹2,581.82Cr vs ₹2,119.46Cr (▲21.81% YoY), EBITDA ₹896.02Cr vs ₹341.84Cr (▲162.11% YoY), PAT ₹713.61Cr vs ₹235.16Cr (▲203.46% YoY). EBITDA Margin 34.70% vs 16.13% (▲1857bps).

Mankind Pharma reported strong Q4 FY26 consolidated financial results. Revenue from operations increased to ₹3,442.93 Cr from ₹3,079.37 Cr (▲11.79% YoY). EBITDA rose to ₹1,044.17 Cr from ₹934.52 Cr (▲11.73% YoY), with EBITDA Margin at 30.33% compared to 30.35% (▼2bps). Net Profit (PAT) grew significantly to ₹559.42 Cr from ₹428.99 Cr (▲30.40% YoY). The board approved the re-appointment of Mr. Satish Kumar Sharma as Whole-Time Director and noted the resignation of Mr. Pramod Gokhale, Global Chief Information Officer. Executive Directors also decided to forgo commission for FY26 to strengthen cash. Ongoing income tax proceedings are an 'Emphasis of Matter' in the auditor's report.